Firm at a glance
SK Capital Partners is a platform private equity firm founded in 2007 and headquartered in New York, NY, per its own website [S1]. The firm has raised more than $9 billion in capital commitments since inception, as of December 31, 2025 [S2].
What they buy
Based on publicly disclosed portfolio holdings, SK Capital Partners appears to concentrate on specialty materials, ingredients, and life sciences businesses [S3]. The firm’s observed portfolio includes companies in material sciences (such as coatings and aerospace materials), specialty ingredients (including food and industrial applications), and life sciences (pharmaceuticals and medical devices) [S3]. The firm typically acquires platform companies rather than pursuing a heavy add-on strategy, with no add-on acquisitions publicly reported in the trailing 12 months as of late 2025 [S3].
Portfolio
Life Sciences
**Apotex** (platform, acquired April 2023) operates in the pharmaceutical sector [S3]. **Spectrum Vascular** is also held in the life sciences category [S3].
Material Sciences
**Axillon Aerospace** (platform, acquired November 2024) serves the aerospace materials market [S3]. **Canlak** (platform, acquired 2021) operates in material sciences [S3]. **Geon Performance Solutions** and **Isolatek International** are also material sciences holdings [S3].
Specialty Ingredients
**Brothers International** (platform, acquired April 2026) is a specialty ingredients business [S3]. **Archroma** (platform, acquired September 2013) operates in specialty ingredients [S3]. **J&K Ingredients** rounds out the specialty ingredients portfolio [S3].
Recent activity (last 24 months)
* **July 2026**: Exit of Milestone Environmental [S4]
* **June 2026**: Exit of Isolatek International [S4]
* **June 2026**: Acquisition of Swixx [S4]
* **April 2026**: Acquisition of Brothers International [S3]
* **June 2025**: Acquisition of bluebird bio (in partnership with Carlyle) [S5]
* **November 2024**: Acquisition of Axillon Aerospace [S3]
How this firm fits a seller
SK Capital Partners appears to target owner-operators and corporate carve-outs in specialty manufacturing and life sciences sectors, based on the composition of its publicly disclosed portfolio [S3]. The firm’s recent activity demonstrates both acquisition and exit capability, with two portfolio exits and three acquisitions completed in the 24 months ending July 2026 [S3][S4][S5]. Sellers in specialty chemicals, advanced materials, pharmaceutical manufacturing, or food ingredients may find sector alignment with SK Capital’s historical investment pattern [S3].
Sources
[S1] https://skcapitalpartners.com/about/ (as of 2025-12-31)
[S2] https://skcapitalpartners.com (as of 2025-12-31)
[S3] https://skcapitalpartners.com/portfolio/ (as of 2025-12-31)
[S4] https://skcapitalpartners.com/news-and-media/ (as of 2025-12-31)
[S5] https://www.orrick.com/en/News/2025/03/Carlyle-and-SK-Capital-to-Acquire-bluebird-bio (as of 2025-03-31)
Frequently asked questions
Does SK Capital Partners buy Life Sciences businesses?
Yes, life sciences represents one of SK Capital’s three primary observed sectors [S3]. The firm acquired Apotex, a pharmaceutical business, in April 2023, and participated in the acquisition of bluebird bio in June 2025 alongside Carlyle [S3][S5]. Spectrum Vascular, a medical device company, is also part of the portfolio [S3].
What companies has SK Capital Partners acquired recently?
SK Capital’s most recent publicly disclosed acquisitions include Brothers International (a specialty ingredients platform acquired in April 2026), Swixx (acquired June 2026), and bluebird bio (acquired June 2025 in partnership with Carlyle) [S3][S4][S5]. The firm also acquired Axillon Aerospace, a material sciences platform, in November 2024 [S3].
Where is SK Capital Partners based and how big is the firm?
SK Capital Partners is based in New York, NY [S2]. The firm has raised more than $9 billion in capital commitments since its founding in 2007, as of December 31, 2025 [S2].
Is SK Capital Partners still actively acquiring?
Yes, SK Capital appears to remain active, with three acquisitions completed in the 24 months ending July 2026: Brothers International (April 2026), Swixx (June 2026), and bluebird bio (June 2025) [S3][S4][S5]. The firm has also executed two exits during this period [S4].
This profile is maintained by CT Acquisitions as an independent third-party reference. CT Acquisitions is not affiliated with, endorsed by, or a representative of the firm profiled. All facts sourced from publicly available materials as of the dates cited.